Blue Dye Is Safe, Effective and Rapid Antimalarial
News Feb 07, 2018 | Original Story from Radboud University Medical Centre.
Research shows that the dye methylene blue is a safe antimalarial that kills malaria parasites at an unprecedented rate. Within two days, patients are cured of the disease and no longer transmit the parasite if they are bitten again by a mosquito. This discovery was made by Radboud university medical center scientists and international colleagues during a research project conducted in Mali. The results will be published in The Lancet Infectious Diseases on February 6th.
The pressure is on when it comes to antimalarial medicines, as malaria parasites are increasingly resistant to the artemisinin-based combination therapies that are currently used. In addition, these medicines do very little to stop the spread of malaria, as the parasites remain in the blood for a long time, with the chance that other mosquitos are infected if they feed on the patient. The parasites split in the patient's red blood cells, forming male and female sex cells (gametocytes). If another mosquito bites the patient, it sucks up the sex cells and these are fertilized in the mosquito's stomach. The offspring then find their way to the mosquito's salivary glands, where the cycle starts again.
Effect after just 48 hours
The gametocytes can stay in a person's body for several weeks following treatment for malaria. In the new study in Mali, Radboudumc researchers added methylene blue to the artemisinin-based combination therapy. Methylene blue is a blue dye that is used in laboratories to distinguish dead cells from living cells. Adding the dye to the antimalaria medicine ensured that patients no longer infected other mosquitos, within as little as 48 hours. Patients who were not given methylene blue were able to infect other mosquitos for at least a week. Researcher Teun Bousema (Radboudumc) coordinated the study which was conducted together with the University of California (UCSF) and the Malaria Research and Training Center (MRTC). Bousema: "We noted that the male parasites disappeared from the bloodstream more quickly than the female parasites."
Encouraged by the promising results of laboratory experiments, Bousema's team has investigated for the first time the effect of methylene blue on the spread of malaria amongst humans. Bousema: "Methylene blue is very promising, because it can prevent the spread of malaria within such a short time following treatment. There are also indications that methylene blue also works well in species that are resistant to certain medicines." The dye is safe and was tolerated well by patients. There is however just one awkward side effect: "I have used it myself, and it turns your urine bright blue. This is something that we need to solve, because it could stop people from using it."
Malaria causes 430?000 deaths every year. Infection is caused by the bite of a malaria-carrying mosquito, and 90% of all deaths are in Africa, mostly amongst children. Malaria prevention focuses primarily on the use of mosquito nets, insecticides and medicine and, as a result, the number of deaths due to malaria has almost halved in the last ten years.
This article has been republished from materials provided by Radboud University Medical Centre. Note: material may have been edited for length and content. For further information, please contact the cited source.
Efficacy and safety of primaquine and methylene blue for prevention of Plasmodium falciparum transmission in Mali: a phase 2, single-blind, randomised controlled trial. Alassane Dicko, Michelle E Roh, Halimatou Diawara, Almahamoudou Mahamar, Harouna M Soumare, Kjerstin Lanke, John Bradley, Koualy Sanogo, Daouda T Kone, Kalifa Diarra, Sekouba Keita, Djibrilla Issiaka, Sekou F Traore, Charles McCulloch, Will J R Stone, Jimee Hwang, Olaf Müller, Joelle M Brown, Vinay Srinivasan, Chris Drakeley, Roly Gosling, Ingrid Chen, Teun Bousema. The Lancet Infectious Diseases. 05 February 2018, DOI: https://doi.org/10.1016/S1473-3099(18)30044-6.
Pre-Clinical Safety in Cancer Drug Development: “Attitude to Safety Needs to Change”News
Many companies involved in cancer drug research and development need to re-think their use of safety data in helping to bring new drugs to cancer patients.
Dr Richard Knight of ApconiX will tell this month’s conference, that greater focus on pre-clinical safety should be fundamental to the development of new cancer therapies.
How Proteins Shape-Shift By the Hour is Central to Figuring Out How Circadian Clocks WorkNews
Scientists utilising X-ray crystallography and NMR spectroscopy have discovered that the way proteins move hour by hour is central to cyanobacteria's circadian clock function.READ MORE
Understanding the Process of Cell DivisionNews
Using multiple techniques such as structural modelling, X-ray scattering, X-ray crystallography and electron microscopy, scientists have found that the Spc110 protein provides a greater function in mitosis originally believed. This information could help understand the process in human cells and the abnormalities that occur in cancer.READ MORE